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Second generation multiple reaction 
monitoring assays for enhanced detection 
of ultra-low abundance Mycobacterium 
tuberculosis peptides in human serum
Carolina Mehaffy1,2, Karen M. Dobos1, Payam Nahid3 and Nicole A. Kruh‑Garcia1*
Abstract 
Background: Mycobacterium tuberculosis (Mtb) is the causative agent of Tuberculosis (TB), the number one cause of 
death due to an infectious disease. TB diagnosis is performed by microscopy, culture or PCR amplification of bacte‑
rial DNA, all of which require patient sputum or the biopsy of infected tissue. Detection of mycobacterial products 
in serum, as biomarkers of diagnosis or disease status would provide an improvement over current methods. Due to 
the low‑abundance of mycobacterial products in serum, we have explored exosome enrichment to improve sensitiv‑
ity. Mtb resides intracellularly where its secreted proteins have been shown to be packaged into host exosomes and 
released into the bloodstream. Exosomes can be readily purified assuring an enrichment of mycobacterial analytes 
from the complex mix of host serum proteins.
Methods: Multiple reaction monitoring assays were optimized for the enhanced detection of 41 Mtb peptides in 
exosomes purified from the serum of individuals with TB. Exosomes isolated from the serum of healthy individuals 
was used to create and validate a unique data analysis algorithm and identify filters to reduce the rate of false posi‑
tives, attributed to host m/z interference. The final optimized method was tested in 40 exosome samples from TB 
positive patients.
Results: Our enhanced methods provide limit of detection and quantification averaging in the low femtomolar 
range for detection of mycobacterial products in serum. At least one mycobacterial peptide was identified in 92.5% 
of the TB positive patients. Four peptides from the Mtb proteins, Cfp2, Mpt32, Mpt64 and BfrB, show normalized total 
peak areas significantly higher in individuals with active TB as compared to healthy controls; three of the peptides 
from these proteins have not previously been associated with serum exosomes from individuals with active TB dis‑
ease. Some of the detected peptides were significantly associated with specific geographical locations, highlighting 
potential markers that can be linked to the Mtb strains circulating within each given region.
Conclusions: An enhanced MRM method to detect ultra‑low abundance Mtb peptides in human serum exosomes is 
demonstrated, highlighting the potential of this methodology for TB diagnostic biomarker development.
Keywords: MRM (Multiple Reaction Monitoring), Mass Spectrometry, Tuberculosis, Exosomes, Mycobacterium 
tuberculosis, Biomarker
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Background
The World Health Organization estimates that 2 billion 
people globally are infected with Mycobacterium tuber-
culosis (Mtb) [1]. One of the biggest hurdles for the global 
control of tuberculosis (TB) is the lack of point-of-care, 
rapid and accurate diagnostic tools. Current diagnos-
tics rely on sputum availability to confirm the presence 
of bacteria by microscopy, live bacilli by culture or using 
molecular tools to detect pathogen DNA. However, 
microscopy only detects 20–80% of all active TB cases [2] 
and although diagnosis by sputum culture is highly sen-
sitive, it can take 4–6 weeks to yield results; this results 
in delays in treatment and continued transmission of dis-
ease in the community. To reduce rates of TB worldwide, 
simpler more easily scalable accurate diagnostics are 
needed, prompting research on novel biomarker discov-
ery and new diagnostic assays, with an emphasis on alter-
native non-sputum diagnostics targeting blood, urine, 
and breath.
We previously demonstrated that during cellular infec-
tion with Mtb, mycobacterial products can be incorpo-
rated into host cell exosomes [3]; the presence of Mtb 
proteins were confirmed in exosomes isolated from 
a variety of fluids from infected animal models [4, 5]. 
Exosomes are 100 nm vesicles generated by all nucleated 
cell types and released into biofluids, including blood, 
urine and sputum [6–10]. Purification of exosomes 
from serum is a facile means to reduce the complexity 
of the fluid and concentrate the encapsulated Mtb pro-
teins. Despite the simplification, the exosomes of inter-
est, that is those derived from the Mtb-infected cells, are 
still a minor component of the entire exosome popula-
tion. Therefore coupling this purification with a sensitive 
downstream detection platform is critical for the detec-
tion of mycobacterial proteins as potential biomarker 
candidates.
Using targeted mass spectrometry we previously con-
ducted a pilot study to determine if 33 mycobacterial 
proteins that we previously identified in cell culture [3] 
and animal studies were also present in exosomes puri-
fied from the serum of individuals diagnosed with active 
disease or known to have latent TB infection [11]. We 
found at least one of the 76 peptides from 27 of the 33 
Mtb proteins in at least a single individual of a cohort or 
57 subjects; the remaining 6 Mtb proteins were not iden-
tified in any of the 57 samples. This discovery experiment 
provided us with a preliminary list of Mtb protein can-
didate biomarkers and a rapid method for triaging pep-
tide candidates to proceed to assay refinement and larger 
verification studies.
The main aim of this study was to enhance an MRM 
method to detect Mtb peptides in serum exosomes from 
TB patients. The aforementioned study by our group 
used 17 unrefined targeted MRM assays to screen for 
the presence of peptides from 33 Mtb proteins [11]. 
The goal of this study is to validate these findings using 
refined MRM methods to reduce the number of channels 
being monitored and improve sensitivity and specific-
ity by spiking isotopically labeled peptide standards and 
including control samples from healthy donors. Novel 
data analysis methodology was applied to confirm the 
presence of 19 low-abundance mycobacterial proteins in 
samples dominated by host proteins. In addition, in this 
study we have analyzed samples from both HIV+ and 
HIV− TB patients. Individuals with HIV/TB co-infection 
are often difficult to diagnose using current techniques 
due to paucibacillary presentation of the disease which 
can compromise detection by microscopy, and while 
detection by culture has higher positivity rates, the col-
lection of several samples is often needed to achieve a 
conclusive diagnosis in these patients [12, 13]. HIV+ 
infected patients also have a lower rate of positivity using 
the TB skin test or Interferon Gamma Release Assays due 
to their inherent immunocompromised status [13–15]. 
Thus, a diagnostic method that can efficiently detect 
both HIV+ and HIV−  TB disease and/or TB infection 
at similar rates is needed. The ultimate goal is to define 
biomarkers of active disease (regardless of HIV status), 
discovered and verified by MRM-MS, and to translate the 
promising candidates to a point-of-care platform for use 
in the field that is independent of complex sample pro-
cessing and high-end instrumentation.
Methods
Study design
Serum samples from TB negative (suspect) and TB posi-
tive patients were obtained from the Foundation for 
Innovative Novel Diagnostics (FIND) specimen reposi-
tory (Geneva, Switzerland). Serum samples from healthy 
donors, with no history of tuberculosis were purchased 
from Bioreclamation IVT (Westbury, NY). All samples 
were stored at −80  °C upon arrival until processed. For 
initial method development and optimization we used 
16  TB negative and 20  TB positive serum samples from 
4 different geographic locations (Table  1); these samples 
were pooled and used as background matrix. For MRM 
method validation we used 20 individual healthy controls 
and 40 individual TB positive serum samples all with cul-
ture confirmed pulmonary tuberculosis (Table 2).
Sample processing
Serum samples (250  µL) were centrifuged to remove 
whole cells/cellular debris. Exoquick (System Biosciences, 
Palo Alto, CA) was added to the cleaned serum at a 4:1 
ratio (sample:reagent), incubated at 4  °C for 30  min, and 
exosomes were pelleted by centrifugation at 1.5  k x g 
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for 30  min, as per manufacturer recommendation. The 
exosomes were suspended in 250 µL of PBS and micro 
bicinchoninic acid assay was performed to quantify pro-
tein content. To construct the pooled matrix stock, 50 µg 
(protein) of purified exosomes from the 36 samples listed 
in Table 1, were mixed. 20 µg of pooled matrix or 50 µg 
(1.18 ±  0.41  µL) of individual exosome sample were run 
into a NuPAGE Novex 4-12% Bis–Tris Gel 1.0 mm gel for 
5  min in NuPAGE MES SDS Running Buffer (Life Tech-
nologies, Carlsbad, CA) to trap the Exoquick polymer 
prior to peptide extraction. In-gel digest with sequencing-
grade trypsin (Roche, Switzerland) was performed at a 
1:20 (enzyme:substrate) ratio, overnight at 37 °C, as previ-
ously described [3]. The extracted peptides were dried and 
suspended at a final concentration of 1 µg/µL in 3% ace-
tonitrile (ACN), 0.5% formic acid (FA) in water.
Peptide standards
Isotope-labelled standards for each of our peptides of inter-
est were purchased from New England Peptide (Gardner, 
MA). All peptides were prepared to a minimum of 95% 
purity and confirmed by HPLC. QC of chromatography was 
monitored by the addition of indexed retention time (iRT) 
standards (Biognosys AG, Switzerland) [16]. 10 nM mixes 
of the isotope-labelled peptide standards and iRT mix at a 
0.4× final concentration were spiked into each sample.
Multiple reaction monitoring
Daily Skyline (64-bit) was used to build and optimize the 
multiple reaction monitoring (MRM) methods for the 
relative quantification of peptides [17]. For this study, two 
MRM methods were built in Skyline. The first (MRM-
1), included 20 peptides from 9 Mtb proteins (Table  3). 
The second method (MRM-2), included 10 Mtb proteins 
and 21 peptides (Table  3). Briefly, FASTA-formatted 
sequences of all 19 proteins were used for in silico tryp-
tic (KR|P) digestion with peptides being selected based 
on previous discovery studies [4, 18]. Both double and 
triple charge precursor ions were empirically tested and 
selected based on their performance. “y” ions for each 
transition were selected based on a library built from 
LC–MS/MS data acquired in an Orbitrap Velos (Thermo 
Scientific) (Additional file 1). The resultant methods were 
exported to Masslynx (Waters Corporation, Milford, 
MA). All method development was performed using a 
10 nM mix of all 41 heavy labeled peptides (K^ = Lysine, 
13C6, 15N2 or R^ =  Arginine, 13C6, 15N4) (New Eng-
land Peptide, Gardner, MA) in a 1  µg/µL matrix back-
ground (as described above). One and a half microliters 
(1.5 µL) of the heavy labeled peptide mix in background 
matrix were then injected into the LC–MS/MS system 
consisting of a Waters nanoACQUITY UPLC coupled to 
a Waters Xevo TQ-S mass spectrometer fitted with a Tri-
zaic source. The instrument was operated with MassLynx 
V4.1 SCN810 (Waters Corporation, Milford, MA). Chro-
matography was performed on a 150  µm ×  50  mm Ion 
key packed with BEH C18 130 Å, 1.7  um. The chroma-
tography length and gradient were optimized to separate 
all peptides as much as possible so that at least 12 points 
per each transition were acquired. Peptides were sepa-
rated using gradient elution with a stable flow rate of 3.06 
µL/min. A linear method consisting of 2 min of equilibra-
tion in 97% buffer A (99.9% water with 0.1% formic acid) 
and 3% buffer B (99.9% ACN with 0.1% formic acid), fol-
lowed by a 45  min linear gradient to 22% buffer B. The 
method finished with 5  min wash at 97% buffer B and 
final equilibration at 3% buffer B for 5 min. The column 
was maintained at 45 °C during analysis, and the samples 
were kept at 4 °C at all times. The mass spectrometer was 
operated in selective reaction monitoring mode using 
electrospray ionization in nanospray positive ion mode, 
with a capillary voltage of 3.6 kV and a source tempera-
ture of 100  °C. Cone voltage was static at 35  V and the 
collision energies were in silico predicted by Skyline for 
each compound individually (Additional file 1). The final 
methods included the selection of the 5 most abundant 
transitions per peptide and the precursor ion with the 
best peak shape and overall signal.
Table 1 Patient breakdown of  samples included in  the 
pooled matrix sample
TB status Smear status HIV status Geography
TB positive, 
n = 20
Positive, n = 12
negative, n = 8
Positive, n = 8
negative, n = 12
Bangladesh, n = 5
South Africa, 
n = 5
Peru, n = 5
Vietnam, n = 5
TB negative, 
n = 16
Positive, n = 4
negative, n = 12
Bangladesh, n = 4
South Africa, 
n = 5
Peru, n = 4
Vietnam, n = 1
Table 2 Patient breakdown of  samples included in  the 
assay verification set
TB status Smear status HIV status Geography
TB positive, 
n = 40
Positive, n = 22
negative, n = 18
Positive, n = 13
negative, n = 27
Bangladesh, 
n = 10
South Africa, 
n = 10
Peru, n = 10
Vietnam, n = 10
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MRM of clinical samples
Trypsin digested clinical samples were resuspended at 
a final concentration of 1 µg/µL in 5% Acetonitrile, 0.1% 
Formic acid containing 10  nM internal standard mix. 
After resuspension each sample was centrifuged 10  min 
to pellet minor impurities. Supernatant was then trans-
ferred to a MS vial and placed in the Xevo-TQS autosam-
pler. One and a half microliters (1.5 µL) were injected into 
the instrument and data was acquired as described above 
monitoring for both heavy and light forms for a total of 10 
transitions per peptide. Blank runs were run every 4 sam-
ples. After MRM analysis of each clinical sample, raw files 
were imported into Skyline where prior to data processing 
in Excel (see section below), each sample was manually 
validated for quality (i.e. retention time; peak shape; and 
intensity and peak boundaries of internal standards). The 
majority of samples were run only once. However in cases 
were the sample did not pass the manual QC (usually due 
to retention time drift), that sample was re-injected at 
least once. In some cases, even after multiple injections, 
data did not pass manual QC. In those case that particular 
sample/peptide was removed from the results.
Determination of limit of detection (LOD) and limit 
of quantification (LOQ)
Serial dilutions (10–0.01  nM) of the heavy labeled pep-
tides were prepared in 1 µg/µL of pooled matrix. 1.5 µL of 
each dilution were injected into the LC–MS/MS system 
described above using a 2 or 4  min window for acquisi-
tion of precursor and transition of each peptide. All dilu-
tion points were run in triplicate. Raw data resulting from 
each of the dilution points were exported into Skyline. 
Peaks were manually validated and boundaries adjusted if 
necessary. Only the final set of transitions after validation 
with clinical samples was used for LOD/LOQ purposes. 
Area under the peak for each of the validated transitions 
was exported into excel and the LOD/LOQ was calculated 
using the LINEST method. Briefly, a linear regression 
was performed and the LOD and LOQ were calculated as 
shown in Eqs. 1 and 2 respectively, where m is the slope of 
the curve and s(y) is the standard deviation of the y values.
All LOD and LOQ values are expressed in fmol/µL 
(Additional file 2).
Liquid chromatography‑multiple reaction monitoring mass 
spectrometry analysis
Data processing was performed using Skyline software. 
Manual inspection and border adjustment of isotopic 
(1)LOD = 3 ∗
m
s
(
y
)
(2)LOQ = 10 ∗
m
s
(
y
)
Table 3 Peptides/proteins included in MRM assays 1 and 2
Name Rv# Peptide Assay Name Rv# Peptide Assay
AcpM Rv2244 IPDEDLAGLR 2 GlcB Rv1837c VVADLTPQNQALLNAR 1
TVGDVVAYIQK 2 FALNAANAR 1
LEEENPEAAQALR 2 NYTAPGGGQFTLPGR 1
Ag85a Rv3804c NDPLLNVGK 2 GlnA1 Rv2220 SVFDDGLAFDGSSIR 2
FLEGFVR 2 GGYFPVAPNDQYVDLR 2
Ag85b Rv1886c PGLPVEYLQVPSPSMGR 2 GroES Rv3418c DVLAVVSK 1
AADMWGPSSDPAWER 2 RIPLDVAEGDTVIYSK 1
Ag85c Rv0129c VQFQGGGPHAVYLLDGLR 1 HspX Rv2031c AELPGVDPDK 1
NDPMVQIPR 1 TVSLPVGADEDDIK 1
FLEGLTLR 1 Mpt32 Rv1860 TTGDPPFPGQPPPVANDTR 1
BfrB Rv3841 EALALALDQER 1 LYASAEATDSK 1
AGANLFELENFVAR 1 Mpt64 Rv1980c SLENYIAQTR 1
Cfp2 Rv2376c GSLVEGGIGGTEAR 1 FLSAATSSTPR 1
SLADPNVSFANK 1 PpiA Rv0009 IALFGNHAPK 2
Cfp10 Rv3874 QELDEISTNIR 2 VIQGFMIQGGDPTGTGR 2
DnaK Rv0350 TTPSIVAFAR 2 HTIFGEVIDAESQR 2
ITQDLLDR 2 MrsA Rv3441c YVLEELR 2
Esat‑6 Rv3875 LAAAWGGSGSEAYQGVQQ 2 TAVEQAAAELGDTGR 2
WDATATELNNALQNLAR 2 SahH Rv3248c GVTEETTTGVLR 1
GarA Rv1827 FLLDQAITSAGR 2 IHVEALGGHLTK 1
LVFLTGPK 2
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standard peaks was performed for each peptide. While 
five transitions were monitored for each peptide, the final 
analysis used 3–5 transitions selected based on low back-
ground/noise level. Any standard peptide which showed 
either an aberrant transition ratio or retention time (RT) 
was used to disqualify the inclusion of the native peptide 
from sample analysis.
Data post‑processing
After initial screening in Skyline, peak areas for indi-
vidual transitions and RTs for both native and standard 
peaks were exported to Excel. In total 19 methods for 
processing the raw data were trialed (data not shown). 
The final method, summarized in Fig. 1, utilized the sum 
of the transition peak areas or total peak area (TPA) for 
each native peptide, followed by normalization by the 
TPA of the isotope-labelled standard (peak area ratio). 
In order for a peak to be qualified for inclusion, three 
minimal qualifications were set: (1) the TPA of the native 
peptide must be composed of values from 3 or more 
transitions, (2) the RT of native transition peaks must be 
within 0.1  min of the standard transition peak, and (3) 
the final normalized TPA must exceed the cut-off deter-
mined by the healthy donor samples. The post data-pro-
cessing protocol, including the first two qualifications for 
inclusion stated above, were applied to the raw values for 
the healthy data to formulate the normalized TPAs. The 
healthy cut-off value was established as the mean nor-
malized TPA plus three times the standard deviation of 
all 20 samples and are summarized in Additional file  3. 
False discovery rates, calculated as the percent of healthy 
samples with nTPA values above the cut-off is included 
in Additional file 3; the maximal number of controls with 
a positive signal in any sample is 1 (5% FDR). The final 
Skyline data files have been deposited to the Panorama 
Repository (https://panoramaweb.org/) [19]. Unpaired, 
two-tailed t-tests were performed using GraphPad Prism 
version 6.00 for Windows (La Jolla, CA). Benjamin-
Hochberg adjustment was used to control the false dis-
covery rate.
Results
LOD/LOQ determination in a pooled exosome matrix
Exosomes isolated from the serum of 16 TB suspects and 
20 TB culture-confirmed patients were pooled to create 
a matrix for the determination of the LOD and LOQ for 
the 41 peptides in our two MRM assays. Most peptides 
displayed sub-nanomolar (nM) LODs (Additional file 2). 
The rationale for creating a pooled matrix for the pur-
poses of establishing LOD and LOQ was to maximize 
the likelihood of selecting the most intense transitions 
for query as we have previously identified several transi-
tions which are highly influenced by the matrix (data not 
shown), and also to reduce bias created by a single rep-
resentative sample. Individual transitions were subject to 
elimination from final analyses if LOD was greater than 
1  nM, with a maximum removal of two transitions per 
peptide.
Identification and geographic diversity of Mtb peptides 
in serum exosomes
Out of 40 patients with active TB, we were able to iden-
tify 35 (87.5%) of them by the identification of at least 
one Mtb peptide monitored in MRM-1 in their serum 
exosomes. MRM-2 was less successful, allowing for 
the identification of only 23 (57.5%) of the TB positive 
patients. Overall, if both assay 1 and 2 results are com-
bined, we see at least one peptide present in 37 out of the 
40 active TB subjects (92.5%). The gain of 2 new positive 
IDs were based on peptide TAVEQAAAELGDTGR from 
the Mtb protein MrsA (Rv3441c) from MRM-2. Three 
patients out of the 40 (7.5%) did not have any bacterial 
peptide identified by either MRM assay, and they varied 
by smear status, HIV status, and region of origin (Fig. 2). 
Sixteen out of 17 (94%) patients missed by sputum smear 
microscopy were identified in our MRM assays by at 
least one peptide (Fig. 2; Additional file 4). There was no 
statistical difference (p = 0.14) between the numbers of 
peptides identified in HIV positive patients (3.2  ±  1.7) 
when compared to those without co-infection (2.4 ± 1.6). 
When stratified by geographical location, patients from 
South Africa displayed the highest numbers of peptides 
Fig. 1 Raw data processing workflow. TPA total peak area (sum of 
transition peaks), nTPA normalized TPA (ratio native/labeled standard), 
TPA healthy cut‑off determined by mean +3× SD
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identified per patient (3.6  ±  1.1), followed by Vietnam 
(2.9  ±  1.5) and lastly, Peru and Bangladesh (2.1  ±  1.9 
and 2.1 ± 1.8, respectively) (Additional file 5). The differ-
ence between the South African subgroup was significant 
when compared to the Peru (p = 0.040) and Bangladesh 
(p = 0.036) subgroups.
The frequency by which each peptide/protein was 
identified in our cohort of 40 samples is summarized 
in Table  4. The top ranking peptide for assay 1 was: 
GSLVEGGIGGTEAR (from the Mtb protein Cfp2); 
this peptide was identified in 24 out of 40 (60%) sam-
ples. Interestingly, this peptide was identified in 90% of 
all of the South African samples, but in only 50% of the 
other three locations (Fig. 2). The difference between the 
normalized TPA in TB patients and healthy individuals 
is statistically different by t test for the GSLVEGGIG-
GTEAR peptide with a p value < 0.001 (Fig. 3). In addi-
tion, the peptides LYASAEATDSK, FLSAATSSTPR, and 
EALALALDQER from Mtb proteins Mpt32, Mpt64, and 
BrfB, respectively, showed a significant (p < 0.05) differ-
ence in signal between those with active disease and the 
healthy cohort (Fig.  3/Additional file  6). When these 4 
significant peptides were stratified by the HIV status of 
each patient, the normalized TPA values between the 
HIV positive and HIV negative groups were not signifi-
cant. Similarly, when stratified by smear status, the dif-
ferences in signal were not statistically different between 
groups. One or more of these 4 peptides was represented 
in 70% of the samples screened. In addition to these four 
peptides we also identified 16 additional peptides that 
were detected in at least 1 or up to 7 individual active TB 
patients and thus also represent candidates for TB dis-
ease biomarkers (Additional file 7). 
Eight peptides in MRM-1 and 9 peptides in MRM-2 
showed no discrimination between healthy individu-
als and those with active tuberculosis (Additional file 8, 
Panel 1 and 2, respectively). This includes: VQFQGGG-
PHAVYLLDGLR (Ag85c), FLEGLTLR (Ag85c), AGAN-
LFELENFVAR (BrfB), SLADPNVSFANK (Cfp2), 
VVADLTPQNQALLNAR (GlcB), TVSLPVGADEDDIK 
(HspX), SLENYIAQTR (Mpt64), and GVTEETTTGVLR 
(SahH) from MRM-1 and TVGDVVAYIQK (AcpM), 
AADMWGPSSDPAWER (Ag85b), ITQDLLDR (DnaK), 
LAAAWGGSGSEAYQGVQQK (Esat-6), FLLDQAIT-
SAGR (GarA), GGYFPVAPNDQYVDLR (GlnA1), 
YVLEELR (MrsA), VIQGFMIQGGDPTGTGR (PpiA), 
and HTIFGEVIDAESQR (PpiA) from MRM-2. As none 
of these peptides showed a signal above the background 
Fig. 2 Stratification of patient samples by HIV status, sputum smear microscopy status, and geography. Each column indicates a single patient 
(n = 40). Black circles indicate the presence of each protein (rows) determined by a normalized TPA of one or more peptides above the healthy 
threshold. Geography is indicated by: B Bangladesh, P Peru, S South Africa, V Vietnam
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level determined by the healthy serum exosomes, these 
17 peptides will be excluded as markers of active tuber-
culosis in future studies. Several of the eliminated pep-
tides correlate with poor LOD values. Since multiple 
peptides are targeted per protein in our assays, the exclu-
sion of these 17 peptides did not eliminate any of the 
Mtb proteins in our original candidate list. Lastly, three 
peptides could not be fully evaluated due to the con-
tribution of the matrix effect, as a baseline value in the 
healthy patient cohort could not be determined (Addi-
tional file 9); the suppression of the 3 standard peptides 
in all 20 healthy exosome samples supports our concern 
of matrix variation and the use of a pooled matrix for the 
LOD calculations.
Discussion
The burden of mycobacterial proteins circulating in 
human serum during active TB infection is currently 
unknown, but based on prior proteomic and molec-
ular-based investigations, it is believed to be of low 
abundance [20]. In this study, we have shown that intra-
cellular mycobacteria contribute to the protein content 
of exosomes [3, 18] and purification of these microvesi-
cles from the serum can serve as an effective method 
of depletion of abundant host proteins (e.g. albumin 
and immunoglobulins) while concentrating the bacte-
rial products of interest. Recent studies have shown 
that proteins from other mycobacterial species, such as 
M. avium [21], as well as other intracellular pathogens, 
such as Helicobacter pylori [22] can be readily detected 
in exosomes. In the current study, we sought to confirm 
and build upon our previous discovery studies in which 
Mtb peptides for 33 unique Mtb proteins were detected 
in human serum or patients with active and/or latent TB 
[11]. Our previous study utilized 17 unrefined targeted 
MRM assays, here we optimized the assays to include all 
selected peptides in two different methods. In this study, 
we included isotopically labeled standards for the first 
time, to confirm peptide identification based on reten-
tion time and fragmentation pattern while also provid-
ing a normalizing tool allowing direct comparison of 
peak areas of a given peptide from sample to sample. 
Ideally, we would have included all of the significant 
peptides determined in our original publication [11], 
however this was not feasible, due to poor performance 
of several of the isotope-labeled peptide standards dur-
ing the development of the MRM assays. Specifically, 
the Mpt64 protein, dictated the selection of alterna-
tive peptides; of the two replacement Mpt64 peptides, 
one remained statistically significant (Fig.  3), while the 
second was nondiscriminatory (Additional file  8). Both 
the addition of the isotope-labeled standards, as well as 
iRT, retention time standard peptides, provide extra QC 
tools that allow us to monitor run-to-run variance. Even 
though RT variability was well within the 2  min moni-
toring window (Additional file 10), the inclusion of iRTs 
and labeled standards allowed us to monitor run-to-run 
variation and to determine the need for re-injection in a 
few cases were RT shifted across the board due poten-
tially to matrix effects. Monitoring of RT variability also 
allowed us to see a pattern in which the late eluting pep-
tides seemed to have a more stable RT. Although we did 
not follow up on the potential reasons for this trend, it 
may be an important factor to consider during develop-
ment of future MRMs.
In this study, we also optimized data analysis to 
increase the stringency of which a given peptide signal 
is considered positive in any given sample. Matching 
retention times to those of the labeled standard, as well 
as the requirement to only count peptides with at least 
three detected transitions were important parameters 
in our algorithm. However, for many peptides, the most 
restrictive filter was the inclusion of the threshold deter-
mined by the normalized TPA in the healthy donor sam-
ples which represents high noise due to the complexity 
of the exosome matrix and which could be mistaken for 
a positive result. Overall, the optimized MRM method 
including the addition of labeled standards and iRTS 
Table 4 Percentage of  samples positively identified with   
each Mtb peptide (left) and protein (right)
In bold italics are the proteins represented by more than one peptide, and in each 
case this results in an additive effect over each peptide considered on its own
Peptide Percent (%) Protein Percent (%)
GSLVEGGIGGTEAR 60 Cfp2 60
LYASAEATDSK 35 Mpt32 38
FLSAATSSTPR 18 Mpt64 18
TAVEQAAAELGDTGR 18 MrsA 18
EALALALDQER 15 BfrB 15
WDATATELNNALQNLAR 15 Esat‑6 15
NDPMVQIPR 10 GroES 13
RIPLDVAEGDTVIYSK 10 Ag85c 10
IHVEALGGHLTK 10 SahH 10
TTPSIVAFAR 8 Ag85a 8
SVFDDGLAFDGSSIR 8 DnaK 8
NDPLLNVGK 8 GlnA1 8
NYTAPGGGQFTLPGR 5 GlcB 8
IALFGNHAPK 5 AcpM 5
FALNAANAR 3 PpiA 5
DVLAVVSK 3 Ag85b 3
AELPGVDPDK 3 Cfp10 3
QELDEISTNIR 3 GarA 3
LVFLTGPK 3 HspX 3
IPDEDLAGLR 3
LEEENPEAAQALR 3
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and the optimized data analysis algorithm, allowed us to 
reduce our original candidate biomarker list from 41 to 
20 highly significant peptides in the context of active TB 
disease.
As noted in our method section, the MRM methods 
presented in this study were optimized with a window 
of 2 or 4  min for scanning of each peptide. Retention 
times were optimized using the labeled peptides spiked 
into a mixture of serum exosomes (our pooled matrix). 
While for the majority of peptides, the retention time 
was stable within that window from sample to sample, 
there are limitations to this type of scheduling, and a few 
peptides, such as FALNAANAR, AGANLFELENFVAR, 
VQFQGGGPHAVYLLDGLR and PGLPVEYLQVP-
SPSMGR, were not routinely detected within our sample 
window as a result. This is likely because the retention 
time for these peptides was very dependent on the matrix 
background and often resulted in either increased or 
decreased retention time outside of the scanning win-
dow. These peptides were also very susceptible to sam-
ple-to-sample variation in the total peak area measured 
for the labeled standard. While scheduling the scanning 
window for each peptide allowed us to include more pep-
tides in a single method without a reduction in sensitiv-
ity, some peptides, such as the ones mentioned above, 
may benefit from an unscheduled method in which all 
channels (one for each peptide) are continuously scanned 
throughout the length of the chromatography. The vari-
ation observed here demonstrates the effect that matrix 
background can have in peptide detection, which was 
further evidenced by the ion suppression we observed 
for three labeled peptide standards (TTGDPPFPGQPP-
PVANDTR, PGLPVEYLQVPSPSMGR, and SVFDDG-
LAFDGSSIR) in the healthy controls.
Importantly, the variation in retention time and ion 
suppression described above demonstrates the impor-
tance of having isotopically labeled peptides spiked in 
each sample such that the correct peak is identified 
(i.e. in cases of retention time drift) and to correctly 
normalize the area under the peak of the native pep-
tide (i.e. ion suppression dependent on matrix back-
ground). The inclusion of isotopically labeled peptides 
Fig. 3 Comparison of normalized total peak areas from the TB patients and healthy individuals. The solid lines indicate the mean nTPA with SD. The 
dotted line represents the threshold created by the average normalized value of the healthy plus 3 times the standard deviation; TB patients were 
designated as positive for a peptide if the TPA was above this threshold. Of the 41 peptides screened, four were statistically more abundant in those 
with active disease (p values detailed in Additional file 6)
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is thus a major improvement from our previous study, 
strengthening the data set by significantly increasing 
the confidence for the detection of bona-fide mycobac-
terial peptides. For future studies, we believe that the 
methods can be improved even further by optimizing 
the method without any scheduling and by increasing 
the number of healthy controls so that more accurate 
mean TPA and more tolerant cut-offs can be applied 
as outliers appear to have a significant impact on the 
threshold.
Blood-based assays are highly desirable for TB diag-
nostics, as they are independent of an individual’s ability 
to produce sputum (i.e. children), as well as remove the 
occupational hazard of transmission during sputum col-
lection. Our study emphasize the benefit of blood based 
biomarkers by highlighting the prevalence of Mtb pro-
teins in serum exosomes in those failed to be identified 
by the first-line diagnostic screening by sputum micros-
copy. Downstream translation of our assay to a point-
of-care platform is in line with the end goal of creating 
an assay that detects active infection faster than sputum 
culture. Of equal importance, the identification of myco-
bacterial proteins in serum exosomes is not affected by 
HIV co-infection; serum biomarkers may have an added 
benefit in detecting disseminated disease often displayed 
in HIV positive patients.
Inclusion of samples from a variety of geographic loca-
tions was another strength of this study, as it provided us 
with a diverse set of samples from persons with disease 
caused by different Mtb strains [23]. Our original work 
focused on a clinical cohort from Uganda [11], at this time 
we did not fully appreciate the potential effect of geogra-
phy on our results which impacted the selection of pro-
tein candidates for this current study. Thus, it is possible 
that we may have missed proteins or peptides that may 
perform better in other geographical locations, including 
those analyzed in the present study. As the mycobacterial 
contribution to the exosome is reflective of the bacterial 
secretome, we sought to identify biomarkers common 
to Mtb complex, independent of lineage or strain. How-
ever, we found that Cfp2 peptides performed best in the 
South Africa cohort (90%) and Mpt32 peptides underper-
formed as a biomarker in Bangladesh (40%, compared to 
60–70% in other regions). Cfp2 is a secreted protein for 
which differences in abundance and secretion among 
Mtb strains had been previously reported by our group 
[24], supporting the idea that some of the differences we 
observed among geographical locations may be associated 
with specific circulating Mtb strains. However, other fac-
tors such as those related to the host (i.e. matrix effects 
favoring ionization of specific peptides), as well as the het-
erogeneity of the infection, may also account for the dif-
ferences seen here, but additional studies are needed.
Conclusions
Through improved sample preparation, enhanced MRM 
assays and optimized data analysis work flow, in this 
study, we were able to find the proverbial Mtb peptide 
“needle” in a serum “haystack”. Whereas the methodol-
ogy as it stands is not suitable for the purpose of TB diag-
nosis in the field setting, it provides confirmation of the 
presence of mycobacterial protein candidates in serum 
exosomes. Additional verification and validation studies 
with larger and more geographically diverse sample sets, 
as well as translation to a point-of-care assay are future 
goals.
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